StockData
Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc. (FLGT) stock

FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3046% below fair value
$24.66−0.19 (-0.76%)

Close on Nov 13, 2026Market cap $678.53MP/E –Yield –

Fulgent Genetics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Fulgent Genetics's EV/EBITDA was 3.8× on Apr 28, 2023, against 2.2× a year earlier. Over the last 4 years it ranged from 1.8× to 466.8×, with a median of 4.5×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 20233.8×+1.9
2022Dec 30, 20221.8×−1.9
2021Dec 31, 20213.7×−14.2
2020Dec 31, 202017.8×−28.1
2018Jan 31, 201846.0×+1.1
2017Dec 29, 201744.9×–

More Fulgent Genetics figures

See a number that looks wrong?